000162705 001__ 162705
000162705 005__ 20230915092402.0
000162705 0247_ $$2doi$$a10.1186/s13195-021-00880-x
000162705 0247_ $$2pmid$$apmid:34384484
000162705 0247_ $$2pmc$$apmc:PMC8361801
000162705 0247_ $$2altmetric$$aaltmetric:111743752
000162705 037__ $$aDZNE-2021-01362
000162705 041__ $$aEnglish
000162705 082__ $$a610
000162705 1001_ $$aBiel, Davina$$b0
000162705 245__ $$aTau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
000162705 260__ $$aLondon$$bBioMed Central$$c2021
000162705 3367_ $$2DRIVER$$aarticle
000162705 3367_ $$2DataCite$$aOutput Types/Journal article
000162705 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655731227_9508
000162705 3367_ $$2BibTeX$$aARTICLE
000162705 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162705 3367_ $$00$$2EndNote$$aJournal Article
000162705 500__ $$aCC BY
000162705 520__ $$aTo systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment.In this longitudinal study, we included 396 cognitively normal to dementia subjects with 18F-Florbetapir/18F-Florbetaben-amyloid-PET, 18F-Flortaucipir-tau-PET and ~ 2-year cognitive follow-up. Annual change rates in global cognition (i.e., MMSE, ADAS13) and episodic memory were calculated via linear-mixed models. We determined global amyloid-PET (Centiloid) plus global and Braak-stage-specific tau-PET SUVRs, which were stratified as positive(+)/negative(-) at pre-established cut-offs, classifying subjects as Braak0/BraakI+/BraakI-IV+/BraakI-VI+/Braakatypical+. In bootstrapped linear regression, we assessed the predictive accuracy of global tau-PET SUVRs vs. Centiloid on subsequent cognitive decline. To test for independent tau vs. amyloid effects, analyses were further controlled for the contrary PET-tracer. Using ANCOVAs, we tested whether more advanced Braak-stage predicted accelerated future cognitive decline. All models were controlled for age, sex, education, diagnosis, and baseline cognition. Lastly, we determined Braak-stage-specific conversion risk to mild cognitive impairment (MCI) or dementia.Baseline global tau-PET SUVRs explained more variance (partial R2) in future cognitive decline than Centiloid across all cognitive tests (Cohen's d ~ 2, all tests p < 0.001) and diagnostic groups. Associations between tau-PET and cognitive decline remained consistent when controlling for Centiloid, while associations between amyloid-PET and cognitive decline were non-significant when controlling for tau-PET. More advanced Braak-stage was associated with gradually worsening future cognitive decline, independent of Centiloid or diagnostic group (p < 0.001), and elevated conversion risk to MCI/dementia.Tau-PET and Braak-staging are highly predictive markers of future cognitive decline and may be promising single-modality estimates for prognostication of patient-specific progression risk in clinical settings.
000162705 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162705 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162705 650_7 $$2Other$$aAlzheimer’s disease
000162705 650_7 $$2Other$$aAmyloid-PET
000162705 650_7 $$2Other$$aBraak-staging
000162705 650_7 $$2Other$$aConversion risk
000162705 650_7 $$2Other$$aTau-PET
000162705 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000162705 650_7 $$2NLM Chemicals$$atau Proteins
000162705 650_2 $$2MeSH$$aAged
000162705 650_2 $$2MeSH$$aAlzheimer Disease: complications
000162705 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000162705 650_2 $$2MeSH$$aAmyloid beta-Peptides
000162705 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000162705 650_2 $$2MeSH$$aHumans
000162705 650_2 $$2MeSH$$aLongitudinal Studies
000162705 650_2 $$2MeSH$$aPositron-Emission Tomography
000162705 650_2 $$2MeSH$$aPrognosis
000162705 650_2 $$2MeSH$$atau Proteins
000162705 7001_ $$0P:(DE-HGF)0$$aBrendel, Matthias$$b1
000162705 7001_ $$0P:(DE-HGF)0$$aRubinski, Anna$$b2
000162705 7001_ $$0P:(DE-2719)2811351$$aBürger, Katharina$$b3$$udzne
000162705 7001_ $$aJanowitz, Daniel$$b4
000162705 7001_ $$0P:(DE-2719)2000030$$aDichgans, Martin$$b5$$udzne
000162705 7001_ $$00000-0001-9736-2283$$aFranzmeier, Nicolai$$b6
000162705 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b7$$eCollaboration Author
000162705 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-021-00880-x$$gVol. 13, no. 1, p. 137$$n1$$p137$$tAlzheimer's research & therapy$$v13$$x1758-9193$$y2021
000162705 8564_ $$uhttps://pub.dzne.de/record/162705/files/DZNE-2021-01362.pdf$$yOpenAccess
000162705 8564_ $$uhttps://pub.dzne.de/record/162705/files/DZNE-2021-01362.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162705 909CO $$ooai:pub.dzne.de:162705$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162705 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000162705 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000030$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000162705 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162705 9141_ $$y2021
000162705 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000162705 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000162705 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000162705 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000162705 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162705 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000162705 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:57Z
000162705 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:57Z
000162705 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-02-14T16:18:57Z
000162705 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000162705 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000162705 9201_ $$0I:(DE-2719)1111015$$kAG Höglinger 2$$lCoordinator of Clinical Parkinson Research$$x0
000162705 980__ $$ajournal
000162705 980__ $$aVDB
000162705 980__ $$aUNRESTRICTED
000162705 980__ $$aI:(DE-2719)1111015
000162705 9801_ $$aFullTexts